At the American Association for Cancer Research (AACR) annual meeting in San Diego, the atmosphere is defined by a sharp juxtaposition: the technical triumph of long-sought oncology targets and the precarious nature of the federal funding that supports them. The scientific focal point this year is the KRAS protein—once considered "undruggable"—which is finally yielding to a new generation of sophisticated inhibitors.
Revolution Medicines has emerged as a central protagonist in this narrative. The company presented robust data at the conference, further validating its approach to targeting KRAS mutations. These findings represent a significant step in refining how clinicians treat some of the most stubborn forms of lung, colorectal, and pancreatic cancers, signaling a shift from experimental hope to clinical utility.
However, the progress in the lab remains tethered to the volatility of Washington’s fiscal priorities. During the opening ceremony, AACR CEO Margaret Foti offered a public defense of the National Institutes of Health (NIH), thanking Congress for rejecting previous budget cuts and increasing funding for the 2026 fiscal year. The reprieve may be short-lived, as the scientific community is already bracing for a proposed $5 billion reduction in the 2027 budget.
Foti characterized these potential cuts as "unacceptable," emphasizing that the momentum of modern oncology cannot be sustained without a stable federal foundation. As Revolution Medicines and its peers push the boundaries of precision medicine, the message from San Diego is clear: the most difficult hurdles in curing cancer may soon be less about biology and more about the endurance of public policy.
With reporting from STAT News.
Source · STAT News (Biotech)
